Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. - Wikidata - awgldk - TriplyDB

Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist.

Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist.

http://www.wikidata.org/entity/Q33521153

about

Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors The APJ receptor: a new therapeutic approach in diabetic treatment Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery.Oxidative stress and metabolic pathologies: from an adipocentric point of view.Biased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine Apelin receptor (APJ) expression during cardiopulmonary bypass in children undergoing surgical repair.The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues.Apelin, diabetes, and obesity.Update on apelin peptides as putative targets for cardiovascular drug discovery.Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy.Apelin/APJ system: a promising therapy target for hypertension.NMDA receptor modulation by the neuropeptide apelin: implications for excitotoxic injury Discovery of a novel small molecule agonist scaffold for the APJ receptor.Directed Molecular Evolution of an Engineered Gammaretroviral Envelope Protein with Dual Receptor Use Shows Stable Maintenance of Both Receptor Specificities.Cardiac action of the first G protein biased small molecule apelin agonist.Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure.By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization.A Time-Resolved FRET Cell-Based Binding Assay for the Apelin Receptor.Pyrene-Apelin Conjugation Modulates Fluorophore- and Peptide-Micelle Interactions.Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential.Convenient Access to Fluorescent Probes by Chemoselective Acylation of Hydrazinopeptides: Application to the Synthesis of the First Far-Red Ligand for Apelin Receptor Imaging.A Non-imaging High Throughput Approach to Chemical Library Screening at the Unmodified Adenosine-A3 Receptor in Living Cells.Apelin receptor signaling: a novel mechanism of endothelial cell polarization.Discovery of a competitive apelin receptor (APJ) antagonist.Apelinergic System Structure and Function.Patent highlights: December 2015-January 2016.

P2860

Q26823618-12FAC6D3-8A1A-47E8-8432-8C924FBBF507 Q27004213-B0661006-8A78-4E90-8812-FFEE822A016E Q27025069-6C6603AA-929D-4318-8C83-73D56EA58463 Q33703037-EC2C55A3-71B0-4B56-81AB-B2A1ADFE793F Q34038044-53C0A153-5DCA-4BA6-BD2D-300EECDD7DDF Q34107370-519227B5-C79C-45C0-836A-05799A7688CB Q34128580-4C562A32-129F-41B0-B6C0-9622E2801B69 Q35125156-297BFE8B-BFF0-435A-BB84-6B357DE2CF4F Q37310459-B7360805-4C89-400B-AE9F-FBC0828DCE10 Q37897155-8E7CCA8A-2100-4128-8E71-0291E20446E2 Q38014484-45117DC6-58D3-4B18-8C15-6428A5C207AF Q38196857-1A6D156C-ECE2-44C5-A783-D1A84DBF5A5A Q38225832-A2EB55CC-22CB-4E02-84EC-1149B6EB06B1 Q38295226-7187DEA4-0EF1-4FFD-ADE6-2DCD9D994763 Q38760395-14730267-5B5F-45F9-BA9F-590C07C403F7 Q38816595-B2365676-EA89-447C-B1F5-44E343D70FE7 Q39541969-B7E542FB-F40D-4A55-80DE-D7D239ABF798 Q41945177-C45AC503-E3D7-4519-93C5-20F8F9CD97EE Q42411890-4CAD24FF-C4C6-4707-BE60-11294ACFFBFA Q48042757-68D66142-A2CF-4601-8DAF-35B21B0048BE Q48063548-3B8E5E4C-84A4-4B02-A0F2-3FC5DB7ED7C9 Q48097017-51FE7969-19A3-4628-85B4-7570804CF594 Q48278244-A1CF80D6-C57D-49F8-86E1-00BFA30FDA5A Q49714374-915A1D06-750A-41C0-8B85-78CAFE9D10C4 Q51353677-97B4C7BC-3441-478B-9248-A6D3ECE5EBF5 Q51768051-5CAD40CE-2195-4EE5-AEE9-CD71C7F13D92 Q53468087-8B4FC2C9-E1DE-41F6-96CB-80D7EF0AEFAA Q54096626-D7A8ED9C-C519-4A9F-A55E-C4B89EEE6D64

P2860

Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist.

http://www.wikidata.org/entity/Q33521153

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Identification and pharmacolog ...... tidic apelin receptor agonist.

@ast

Identification and pharmacolog ...... tidic apelin receptor agonist.

@en

Identification and pharmacolog ...... tidic apelin receptor agonist.

@nl

type

label

Identification and pharmacolog ...... tidic apelin receptor agonist.

@ast

Identification and pharmacolog ...... tidic apelin receptor agonist.

@en

Identification and pharmacolog ...... tidic apelin receptor agonist.

@nl

prefLabel

Identification and pharmacolog ...... tidic apelin receptor agonist.

@ast

Identification and pharmacolog ...... tidic apelin receptor agonist.

@en

Identification and pharmacolog ...... tidic apelin receptor agonist.

@nl

P1433

Q33521153-4D3D6C11-9A04-481A-9076-9FC181604BC7

P1476

Q33521153-1F8B5EC0-B4AA-4BC4-898E-67F47A7E670B

P2093

Q33521153-01142E17-8339-429F-820D-EDBBA5612290

Q33521153-28E21114-5AC2-4E97-A79D-14E892068F79

Q33521153-458824B3-55F8-4F4D-A2AF-C71C1E5A24D7

Q33521153-6CCBC3C3-E738-449E-9037-3218076585BA

Q33521153-797E6D1E-2FBD-47E0-BC51-24E35882A2E8

Q33521153-79944BC6-D563-411D-9161-6DD318F98C7F

Q33521153-845E5208-9E4B-479C-AD2C-6597DAB2BD32

Q33521153-A3CF7D64-7CA2-42E5-B142-2B3EF2F3135A

Q33521153-CB9DB65E-3E78-43F0-8627-C4C668DA1E6F

Q33521153-CDBFBEF8-59AF-4069-9E6B-A5FEC02A4C9E

P304

Q33521153-34814BC1-2B53-4C90-81B3-E5C4D0FAF7FE

P31

Q33521153-DD1F1BF2-FDBA-465F-BAE1-D850775F4CA9

P356

Q33521153-DDF12059-0B59-49A1-90A6-42A48A951F06

P407

Q33521153-947C85C6-C8C2-4876-B641-04948F69F159

P433

Q33521153-525CC38C-900A-4819-BD74-B5E35142BC3E

P478

Q33521153-38465252-F4A2-4D70-9766-6F7648D76271

P50

Q33521153-03303A0C-2B18-4CA1-BD7B-1E38BAC7AFBC

Q33521153-3EB5FE2F-9D2F-42D5-8E4C-B011F0BBC16E

Q33521153-855CDBD9-906A-4FDB-98A0-48D4154E65C1

Q33521153-94155F85-1807-4876-95DF-B1F0DCAC7E98

P577

Q33521153-288DE675-A5B8-47CD-8734-1D244831480D

P5875

Q33521153-C15B1A07-DE49-4154-BFE9-327DF07E489F

P698

Q33521153-6D85958B-7F3D-475C-B0FC-3C943380C8FE

P921

Q33521153-0C5391B6-03D6-48B9-9304-5743ABEEEB45

P356

P1433

P1476

Identification and pharmacolog ...... tidic apelin receptor agonist.

@en

P2093

Alain Berdeaux

http://www.w3.org/2001/XMLSchema#string

Bernard Maigret

http://www.w3.org/2001/XMLSchema#string

Catherine Llorens-Cortes

http://www.w3.org/2001/XMLSchema#string

Christel Franchet

http://www.w3.org/2001/XMLSchema#string

Fabrice Guillier

http://www.w3.org/2001/XMLSchema#string

Hadjila Chabane

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Galzi

http://www.w3.org/2001/XMLSchema#string

Marcel Hibert

http://www.w3.org/2001/XMLSchema#string

Melissande Le Jouan

http://www.w3.org/2001/XMLSchema#string

Nadia De Mota

http://www.w3.org/2001/XMLSchema#string

P304

1506-1517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.09-140715

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Bonnet

Xavier Iturrioz

P577

2009-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40812284

http://www.w3.org/2001/XMLSchema#string

P698

20040517

http://www.w3.org/2001/XMLSchema#string

P921